Teva 'optimistic' opioid settlement could come within year following historic $26B deal with Johnson & Johnson, 3 distributors
Jul 28, 2021 11:26am CEO Kåre Schultz said on Wednesday during the company's second quarter earnings call he wouldn’t be surprised if Teva ends up paying over a longer period than the initially planned 10-year timeframe. (Teva) When Johnson & Johnson and three major drug distributors reached a $26 billion settlement to resolve thousands of opioid lawsuits last week, one big pharma player was noticeably missing: Teva. That’s because the generic giant hasn’t proffered as much cash as the other four companies in its potential deal, which includes $250 million in cash and $23 billion in ...
Source: fiercepharma.com
